High-resolution manometry (HRM), along with the analysis algorithms characterized in the Chicago Classification (CC) first proposed in 2008, have led to a major restructuring of the classification of oesophageal motility disorders. The inherently quantitative output of HRM devices fuelled enthusiastic expectation among motility experts that these advances would add a level of precision to the diagnosis of oesophageal motility disorders that was not previously possible. Nowhere was this advance more evident than in our concept of achalasia, now differentiated into subtypes as a direct result of HRM. Coincident with the assimilation of HRM into clinical practice was the development of a major therapeutic intervention for the management of oesophageal motility disorders, per-oral endoscopic myotomy (POEM). Not only does the POEM procedure provide a therapeutic option for myotomy with reduced morbidity relative to laparoscopic or open myotomy, but it also enables a calibrated intervention that is customized to patient-specific physiology. Together, these develop ments fostered an increasing emphasis on targeting therapy to specific aspects of oesophageal dysfunction, as measured by physiological testing, rather than discrete diagnoses. Again, nowhere is this evolution more evident than in our strategies for managing achalasia. This Consensus Statement examines the effect of HRM on our current understanding of oesophageal motility disorders with a focus on how this technology has affected the diagnosis, epidemiology and management of achalasia and achalasia-like syndromes
; on behalf of the International Working Group for Disorders of Gastrointestinal Motility and Function
Abstract | High-resolution manometry (HRM) and new analysis algorithms, summarized in the Chicago Classification, have led to a restructured classification of oesophageal motility disorders. This advance has led to increased detection of clinically relevant disorders, in particular achalasia. It has become apparent that the cardinal feature of achalasia -impaired lower oesophageal sphincter (LES) relaxation -can occur in several disease phenotypes: without peristalsis (type I), with pan-oesophageal pressurization (type II), with premature (spastic) distal oesophageal contractions (type III), or with preserved peristalsis (outlet obstruction). Furthermore, no manometric pattern is perfectly sensitive or specific for achalasia caused by a myenteric plexopathy, and there is no biomarker for this pathology. Consequently, physiological testing reveals other syndromes not meeting achalasia criteria that also benefit from therapies formerly reserved for achalasia. These findings have become particularly relevant with the development of a minimally invasive technique for performing a long oesophageal myotomy, the per-oral endoscopic myotomy (POEM). Optimal management is to render treatment in a phenotype-specific manner; that is, POEM calibrated to patient-specific physiology for spastic achalasia and the spastic disorders, and more conservative strategies such as pneumatic dilation for the disorders limited to the LES. This Consensus Statement examines the effect of HRM on our understanding of oesophageal motility disorders, with a focus on the diagnosis, epidemiology and management of achalasia and achalasia-like syndromes.
Methods
The core HRM steering committee (P.J.K., A.J.B, M.F., C.P.G., S.R., A.J.P.M.S. and J.E.P.) was appointed by the International Working Group for Disorders of Gastrointestinal Motility and Function (http://www. idigest.ch/) to oversee the drafting and updating of the CC of oesophageal motility disorders. The first major version of the CC was published in 2009 after the inaugural meeting of the International HRM Working Group in San Diego, USA, in 2008. The next major update followed from a meeting of the International HRM Working Group in Ascona, Switzerland, in 2011 and was endorsed by numerous international motility and gastro enterology societies. An expanded International HRM Working Group met in Chicago, USA, in conjunction with Digestive Disease Week 2014 to formulate the CC v3.0, which was then finalized at the 2015 meeting of the International Working Group for Disorders of Gastrointestinal Motility and Function in Ascona. Since the publication of CC v3.0 in 2015 (REF. 1), which was also endorsed by numerous international motility societies, the clinical application of HRM has increased rapidly, as have the number of relevant clinical and investigational publications. Consequently, as part of this series of Consensus Statements on gastrointestinal motility, the HRM steering committee performed focused literature searches to explore the effect of CC v3.0 on the management of oesophageal motility disorders. A draft manu script was initially formulated by one of the authors (P.J.K.), which was then circulated among all steering committee members for extensive discussion and debate. Consensus on the final content of the manuscript was achieved through careful evaluation and discussion of the available literature.
High-resolution manometry
Oesophageal motility testing was revolutionized with the widespread adoption of HRM in the early 2000s. With HRM, intraluminal pressure recordings are obtained with multiple closely spaced pressure sensors such that there is negligible loss of pressure data between sensors 2 . Manometric data are most commonly viewed and analysed in the form of pressure topo graphy (FIG. 1) . Alternatively called isobaric contour plots or, in recognition of the individual who pioneered these, Clouse plots 3, 4 , these colour plots use a coordinate system of time on the x-axis, sensor position in the oesophagus on the y-axis, and pressure values represented by colour within that coordinate system. Hence, although not synony mous, HRM is a prerequisite for creating accurate pressure topography plots, and we will henceforth refer to the combined technology as HRM.
HRM is not a complementary technology to conventional manometry; rather, it is replacement technology that has rendered conventional oesophageal manometry obsolete. Although some practitioners resisted this evolution, HRM has become 'conventional manometry' and most newly trained gastroenterologists are completely unfamiliar with the line-tracing manometry format of old. HRM has several advantages over conventional manometry: it is easier to perform high-quality studies of uniform format; a single probe position encompasses the entire oesophagus, negating the need to repeatedly reposition it during the study; the data format lends itself to the development of standardized objective measures of peristaltic and sphincter function; the process of interpretation is more intuitive and more easily learned by trainees or new practitioners 5, 6 ; and it results in an increased detection of achalasia and other clinically relevant diagnoses among patients with dysphagia 7 . Nonetheless, HRM is still a technique requiring special expertise and training to perform high-quality studies [8] [9] [10] . HRM is also more expensive than conventional manometry, and invites overinterpretation in inexperienced hands. Whether the person performing the study is a nurse, technician or physician, they must be able to assess the technical adequacy of the study as they are doing it. This assessment requires that they have sufficient knowledge to determine proper catheter positioning, recognize common artefacts and recognize equipment malfunction.
The Chicago Classification
The CC is a method for interpreting HRM studies and classifying oesophageal motility disorders. This classification scheme has been a work in progress, most recently summarized in 2015 as CC v3.0 (REF. 
Analysis metrics utilized in the CC
The concept of the CC is to apply standardized metrics in the analysis of HRM studies to identify oesophageal motility disorders. Primarily, this approach applies to patients with non-obstructive dysphagia and/or oesopha geal chest pain without a history of surgery affecting oesophageal function. Motility disorders are categorized as major in the CC if they are never found in normal healthy individuals or minor if there is overlap with observations in normal individuals. The scheme is based on an analysis of ten 5 ml swallows performed in a supine or reclined position; however, reference ranges using the same metrics have also been published for studies conducted in the sitting position 11 . The CC is inherently a quantitative analysis, which has important technical ramifications because of manufacturerspecific performance characteristics. The device utilized in the investigational work for the development of the CC was the apparatus designed by Sierra Scientific ( currently marketed by Medtronic, UK). Hence, the published normal values and discriminant characteristics of these metrics pertain to studies using Sierra devices and are different for studies using other equipment 12 . This consideration is especially relevant with respect to measuring the completeness of oesophagogastric junction (EGJ) relaxation, key to the diagnosis of achalasia. Measurements of sphincter relaxation are notoriously susceptible to artefacts caused by oesophageal movement relative to the sensor during relaxation, the axial and longitudinal asymmetry of the sphincter, and dynamic fluctuations in OGJ pressure attributable to respiration and cardiac pulsation. The numerical values discussed herein pertain to the Sierra device.
Assessing lower oesophageal sphincter relaxation. The analysis of an HRM study begins with an assessment of the adequacy of deglutitive lower oesophageal sphincter (LES) relaxation, abnormality of which is a cardinal finding in achalasia. Several nuances of quantifying LES relaxation emerge in HRM 1, 8 . First, other than in instances of hiatal hernia in which there is spatial separation of the LES and crural diaphragm, intraluminal sensors are measuring EGJ relaxation, not LES relaxation. Second, the sphincter moves proximally during swallowing, transient LES relaxations and spastic contractions as a consequence of oesophageal longitudinal muscle contraction; in extreme instances this proximal movement can be as much as 9 cm. Consequently, a sensor positioned within the sphincter at rest can be distal to the sphincter after swallowing and subject to the artefact of 'pseudorelaxation' (REFS 13, 14) (FIG. 1) . Third, intraluminal EGJ pressure is affected by more than just the LES. At any one instance, EGJ pressure is the greatest of three possible contributing factors: LES pressure; pressure exerted by the crural diaphragm; or intra bolus pressure as the swallowed water becomes pressurized to traverse the EGJ 15 . These considerations led to the develop ment of the HRM EGJ relaxation metric of integrated relaxation pressure (IRP) 14 . IRP is defined as the mean pressure during the 4 s of maximal deglutitive relaxation in the 10 s window beginning at upper oesophageal sphincter (UES) relaxation and referenced to gastric pressure. Contributing times to the IRP can be contiguous or non-contiguous when interrupted by diaphragmatic contraction. The IRP Nature Reviews | Gastroenterology & Hepatology is expressed as a median value of the 10 test swallows with 15 mmHg being the upper limit of normal 1 . An IRP >15 mmHg defines EGJ outflow obstruction (EGJOO). However, as with any metric, an IRP >15 mmHg is neither 100% sensitive nor 100% specific for clinically relevant EGJOO. In the initial description of this metric, which was applied to 400 patients (including 62 with achalasia) and 73 healthy individuals, the IRP cut-off of 15 mmHg was found to be 98% sensitive and 96% specific for the detection of achalasia 13 . Assessing peristalsis. After defining the adequacy of EGJ relaxation, the next step in the hierarchical analysis of an HRM study is to characterize peristalsis. The metrics used to identify the major motility disorders in CC v3.0 are the distal contractile integral (DCI) and the distal latency (FIG. 2) . The DCI integrates the length, vigor and persistence of the distal oesophageal contraction from the pressure minima at the transition zone to the EGJ. Conceptually, if the Clouse plot of distal oesophageal contraction is envisioned as a 3D solid, the 'footprint' of the solid is time (s) multiplied by length of the distal oesophageal segment (cm) and the height of the solid is pressure. The DCI is the volume of that solid spanning from 20 mmHg at the base to its peak(s) expressed as mmHg•s•cm. The lower 20 mmHg is excluded from the calculation to minimize the contribution of pressure artefacts that are unrelated to oesophageal contraction. The DCI is used to define hypercontractile swallows (DCI >8,000 mmHg•s•cm), weak swallows (DCI <450 mmHg•s•cm) and failed peristalsis (DCI <100 mmHg•s•cm) (FIG. 2) .
The other major abnormality of peristalsis is of premature contractions, defined by the distal latency. Physiologically, premature contractions imply dysfunction of the inhibitory neurons of the oesophageal myenteric plexus and are the defining characteristic of distal oesophageal spasm and type III achalasia in CC v3.0 (REF. 16 ). The distal latency is measured as the interval from UES relaxation to the contractile deceleration point (CDP), the inflection point in the wave front velocity just proximal to the EGJ. 15 A distal latency <4.5 s defines a premature contraction. Hence, the CDP is a key landmark in the assessment of the contraction pattern. Propagation velocity slows at the CDP, demarcating the transition from peristalsis to ampullary emptying, which is mechanistically distinct from peristalsis. However, the CDP can be difficult to localize in instances of atypical peristaltic architecture or compartmentalized pressurization, leading to the stipulation of two further conditions: to overcome issues associated with atypical peristaltic architecture, the CDP must be localized to within 3 cm of the LES 17 ; and in instances of compartmentalized pressurization, the CDP needs to be localized along an isobaric contour line of greater magnitude than the compartmentalized intrabolus pressure.
Achalasia phenotypes
Aside from objectifying the definition of impaired deglutitive EGJ relaxation and thereby improving the sensitivity of manometry for detecting achalasia, HRM has also established a subclassification of achalasia based on the associated pattern of contractility proximal to the sphincter 18 (TABLE 1) . A diagnosis of achalasia requires both impaired deglutitive EGJ relaxation and absent peristalsis 19 . However, absent peristalsis is not synonymous with absent pressurization or contractility.
In fact, both oesophageal pressurization and nonperistaltic contractility are quite common in achalasia (FIG. 3) . In conventional manometry, such instances were often referred to as 'vigorous achalasia' , although that term never had a clear defin ition and its use was discouraged in the pre-HRM oesophageal motor disorder classification scheme 20 . A seminal observation in the early days of HRM was that absent peristalsis accompanying impaired EGJ relaxation can occur with three associated patterns of oesophageal contractility: negligible pressurization within the oesophagus, defining classical or type I achalasia; pan-oesophageal pressurization wherein contractions that do not occlude the lumen result in uniform pressurization within the oesophagus spanning from the UES to the LES, defining type II achalasia (achalasia with pressurization); or premature (short latency) spastic contractions within the distal oesophagus, defining type III, or spastic, achalasia 19 (FIG. 3) . In multiple reported HRM series from major centers worldwide, type II achalasia is the most common subtype 18, [21] [22] [23] . Paradoxically, type II achalasia would often go undetected or misdiagnosed with conventional manometry because of LES pseudo relaxation during pan-oesophageal pressurization, or because panoesophageal pressurization was mistaken for a spastic contraction, resulting in an alternative diagnosis of distal oesophageal spasm.
Achalasia syndromes beyond CC subtypes Classification schemes are important and the CC v3.0 has gone a long way in objectifying the diagnosis of achalasia. However, the fact that the CC has already gone through three iterations emphasizes that this classification is a work in progress and that no classification scheme will ever be perfect. After all, no biomarker of achalasia exists and although we recognize that in typical cases the underlying pathology is of a myenteric plexopathy 24 , the diagnosis is rarely, if ever, established by neuropathology. Rather, the diagnosis is established using physiological tests to demonstrate that symptomatic oesophageal dysfunction (potentially dysphagia, regurgitation, chest pain or heartburn) is occurring as a result of oesophageal outflow obstruction that cannot be attributed to a stricture, tumour, vascular structure, implanted device or infiltrating process 19 . Consequently, it is imperative to recognize two important limitations of CC v3.0 with respect to the diagnosis of achalasia: some patients have achalasia and an IRP <15 mmHg; and there can be instances in which peristalsis is preserved (TABLE 2) . Furthermore, the distinction between achalasia subtypes (especially type I and II) can be difficult because some cases can have features of more than one subtype and the disease evolves over a variable time span. When the disease develops slowly, there is a gradual transition from normal peristalsis and normal EGJ relaxation to absent peristalsis and EGJOO; at intermediate time points in the development of the disease, these abnormalities might or might not achieve the requisite diagnostic threshold.
Normal IRP achalasia
A prerequisite for IRP to be >15 mmHg is that EGJ pressure is >15 mmHg, which is not always the case in achalasia, particularly in type I disease (TABLE 2) . This finding is explained partly because, in the absence of oesophageal pressurization, IRP becomes solely dependent on EGJ contractility, and partly because some patients with achalasia have a very low LES pressure, especially those with advanced disease. Historically, recognition of this limitation led some practitioners of conventional manometry to express LES relaxation as a percentage relaxation from baseline pressure rather than as a nadir pressure, but that approach ultimately fails in the opposite (more common) instance of patients with achalasia with high EGJ pressure wherein the percentage relaxation is 'normal' but the residual pressure is high. Another approach is to alter the IRP cut-off for defining type I achalasia. This method was proposed by Lin et al. 25 on the basis of a classification and regression tree model that suggested that for type I achalasia the optimal IRP cut-off for EGJ relaxation was 10 mmHg. However, the International Working Group formulating CC v3.0 rejected that proposal, arguing that it would be too confusing. Rather, they suggested that the diagnosis of achalasia still be considered if there was a borderline median IRP with evidence of oesophageal pressurization. However, not even that criteria suffices, as evidenced by a study published in 2017 that reported extremely low IRP values (3 mmHg, 5 mmHg) in some patients with achalasia in whom impaired sphincter function was demonstrable using functional luminal imaging probe (FLIP) technology and stasis on the barium oesophagram 26 . Issues of defining abnormal EGJ relaxation result from the fundamental limitation that no metric or technology has perfect sensitivity and specificity for detecting relevant sphincter dysfunction, and in marginal or atypical cases one has to consider all available evidence from multiple studies, rather than one single parameter. There are instances in which measurement of the distensibility index, a metric relating EGJ opening diameter to intraluminal distensile pressure, with FLIP using a threshold of 2.8 mm 2 per mmHg will be the most helpful in diagnosing abnormal EGJ function 27 (FIG. 4) .
Conversely, in other instances, diagnosis might be achieved via minimal bolus flow time ascertained during high-resolution impedance mano metry 28, 29 , a timed barium oesophagram 26 , or a rapid drink challenge 30, 31 . However, in most cases an IRP >15 mmHg will suffice to detect impaired EGJ relaxation.
Achalasia with preserved peristalsis
In early iterations of the CC, type III achalasia was defined by either the occurrence of spastic contractions or "fragments of peristalsis" 32, 33 . That definition was changed to premature contractions for ≥20% of swallows in CC v3.0 (TABLE 1) because of the realization that fragments of peristalsis were common and were not speci fic to type III achalasia. In fact, fragments of peristalsis frequently emerge after achalasia is treated by relieving the outflow obstruction with myotomy (FIG. 5) .
Roman et al. 34 demonstrated this effect in a series of patients with achalasia studied with HRM before and after undergoing Heller myotomy surgery. More than half of the 30 patients studied exhibited instances of either intact peristaltic contractions or remnants of distal peristalsis in their HRM study after treatment.
Peristalsis recovery after treatment. Recovery of peristalsis after Heller myotomy emphasizes the hetero geneity of achalasia pathogenesis. Although distal oesophageal myenteric plexus degeneration is a pathological feature of achalasia, the pattern and intensity of inflammation are variable 24 . Recovery of distal peri stalsis after myotomy suggests that neuronal dysfunction limited to the LES might dominate in some patients with achalasia. Instances of short-segment achalasia were reported before the advent of HRM 35 , and in these cases the absent peristalsis observed before treatment was a consequence of EGJ obstruction. This phenomenon was demonstrated by Mittal et al. 36 in cats by placing ligatures around the LES, which resulted in failed peristalsis with increasing degrees of outflow obstruction. In that model, peri stalsis promptly returns after ligature removal 37 . In humans, laparo scopic adjustable gastric band placement as a treatment for obesity can represent an analogous model of EGJ obstruction. Manometric features of achalasia have been observed after laparoscopic adjustable gastric band placement, and peristalsis has been restored after band deflation or removal in some cases 38, 39 . Partial recovery of peristalsis after myotomy might also be indicative of the progressive stages of achalasia pathogenesis. Support for this hypothesis is found in a classic study of achalasia neuropathology, with the observation that in vigorous achalasia (preserved oesophageal contractility) myenteric plexus inflammation was associated with a normal number of ganglion cells without neural fibrosis, whereas classic achalasia was associated with neural fibrosis and few, if any, ganglion cells 40 . The authors concluded that inflammation was an early stage in the disease, eventually followed by aganglionosis and fibrosis. Such progression was also suggested in a study published in 2016 that showed greater ganglion cell loss in type I achalasia than in type II achalasia, supporting the notion that type II is an earlier stage of the disease 41 . Within this concept, recovery of peristalsis after myotomy might indicate an inflamed, but surviving, distal oesophageal myenteric plexus, whereas lack of recovery might indicate progression to aganglionosis. In support of this hypothesis, post-myotomy peristalsis in the Roman et al. study was usually characterized as weak with low DCI values 34 . Along the same lines, FLIP detected non-occluding or occluding contractions in 10 of 10 patients with type III achalasia, two-thirds of the 26 patients with type II achalasia tested and one-third of the 15 patients with type I achalasia 42 .
EGJOO. In addition to the three subtypes of achalasia, CC v3.0 recognizes EGJOO as another potential phenotype of achalasia (FIG. 3d; TABLE 2 ). In this entity, IRP is >15 mmHg, but there is sufficient evidence of peristalsis such that criteria for type I, type II or type III achalasia are not met. From the outset, those with EGJOO were recognized to be a heterogeneous group of patients, only some of whom benefited from achalasia treatments 43 . EGJ Consequently, EGJOO always requires more intense clinical evaluation (for example, with endoscopic ultrasono graphy, FLIP and CT, among others) to clarify its aetiology. Potential aetio logies include incompletely expressed or early achalasia, oesophageal wall stiffness from an infiltrative disease or cancer, vascular obstruction, sliding or para-oesophageal hiatal hernia, abdominal obesity or the effects of opiates 44 . Similar findings are found also in patients with dysphagia after restrictive, antireflux and bariatric procedures [45] [46] [47] . However, two series published in the past few years found that many patients with EGJOO were minimally symptomatic or asymptomatic, that in 20-40% of cases the 'disorder' resolved spontaneously, and that only 12-40% were treated (conservatively) as having achalasia 48, 49 . To increase the specificity of an elevated IRP with preserved peristalsis for the diagnosis of EGJOO, provocative maneuvers or adjunctive studies, such as a rapid drink challenge or solid test meal, can be applied 50, 31 . Increasing the volume and/or viscosity of the bolus increases oesophageal pressurization and, therefore, IRP in the presence of clinically significant EGJOO. The clinical utility of this approach was demonstrated in a prospective study of patients with persistent symptoms after fundoplication surgery. The diagnostic yield of EGJOO in this group of patients was increased by inclusion of solids in HRM studies, and symptoms improved after pneumatic dilation 46 .
Achalasia epidemiology re-examined A common observation among early adopters of HRM was increased detection of achalasia, leading to the suspicion that the disease was more common than previously reported. Several factors make it difficult to obtain accurate figures on the incidence and prevalence of achalasia. Importantly, in the absence of a disease biomarker, achalasia detection depends on physio logical testing, which has never been done on an adequately sized population-based sample to get meaningful data on achalasia. Consequently, available estimates, reporting annual incidence and prevalence values of about 1 per 100,000 and 10 per 100,000, respectively 51 , are based on the assumption that all cases are detected. This assumption is obviously not true. One immediate inconsistency is the 1:10 incidence to prevalence ratio. Achalasia is not a fatal disease and there is no reason to think that affected individuals live with the disease for a mean of only 10 years (as would be the case if that ratio were correct). Furthermore, there is the major issue that achalasia in many patients is undetected throughout the life course or is misdiagnosed. It is in this context that the effect of the widespread adoption of HRM on estimates of incidence and prevalence needs to be considered. An accurate estimate of the incidence and prevalence of achalasia, as defined by HRM, would require a very large population-based HRM study. That not being practical, one alternative approach would be to study a region with a captive population because of reimbursement considerations for manometry. Such a report, partially based on HRM, was published in 2017 on data from South Australia, a state in which all manometry studies are performed at three expert centers and detailed databases are maintained 52 . Their analysis concluded that the adult incidence of achalasia was 2.3-2.8 per 100,000 for the decade ending in 2013. Another alternative methodology would be to study a population in the vicinity of a high-visibility, well-established practice that has been doing high-quality HRM studies since the introduction of the technology. The group pioneering the development of the CC reported such a study in 2017 (REF. 53 ). That report analysed the incidence and prevalence of achalasia over a 10-year period for the 250,000 adults living in the vicinity of Northwestern Memorial Hospital (NMH), Chicago, USA, as defined by their home address zip codes. This approach still yields a systematic underestimate because it assumed that every incident achalasia case in the NMH neighbourhood was diagnosed, Nature Reviews | Gastroenterology & Hepatology and that every incident case was diagnosed and managed at NMH. Neither of these assumptions was true because the fraction of achalasia cases that go undetected is unknown, and, although NMH does command a large local market share, the reality of competing insurance networks, the uninsured and the underinsured in the USA make it a virtual certainty that a substantial number of patients were managed elsewhere. Nonetheless, the estimated incidence of achalasia averaged 2.92 per 100,000 during a 10-year period and the prevalence progressively increased from 15.64 to 32.58 per 100,000 over the same period, with no plateau evident. The age of diagnosis was spread evenly among the adult decades of life with a mean age of 56 years. Consequently, the rising prevalence is consistent with the hypothesis that the low-mortality nature of achalasia led the Chicago group to accumulate cases over time 54 . Projecting those prevalence estimates forward, and assuming an average life expectance of 82 years in that part of Chicago, achalasia prevalence is anticipated to stabilize at a value about 26 times the incidence or, in this case, at 76 per 100,000 population, approaching 0.1%. At this estimated prevalence, achalasia is still a rare disease, but is substantially more prevalent than the prior estimates of 10 per 100,000.
Phenotype-directed treatment As described in TABLE 1 and TABLE 2 , all phenotypes of achalasia share the common element of EGJOO, but the associated pattern of oesophageal contractility varies from absent contractility at one extreme to spastic contractions at the other. One of the original observations with the description of achalasia phenotypes was that treatment outcome was dependent on phenotype, with outcomes being best in type II and probably worst in type III 18 . Those observations have subsequently been confirmed by a number of other studies [21] [22] [23] (TABLE 3) .
No current treatment halts the immunologically driven plexopathy that drives development of idiopathic achalasia 24 . Rather, treatments aim to alleviate the hallmark abnormality of the disease, oesophageal outflow obstruction. Going forward, it is time to compare therapies within disease subtypes, be that achalasia types I, II, or III, or the achalasia syndromes detailed in TABLE 2, as each subtype has unique treatment considerations and each could well have a unique optimal manage ment strategy. Relevant features to consider are deglutitive sphincter dysfunction, mechanical oesophageal outflow obstruction, obstructive contractility of the distal oesophagus, and the severity of oesophageal dilatation with sigmoid deformation.
LHM and pneumatic dilation
Until the past 5 years, the main durable treatment options for achalasia were laparoscopic Heller myotomy (LHM) or pneumatic dilation. Pneumatic dilation is performed with a noncompliant, cylindrical balloon (30 mm, 35 mm or 40 mm in diameter) positioned across the LES with fluoroscopic guidance and inflated using a handheld manometer. A study published in 2015 described a modification of this technique, with the introduction of a 30 mm diameter hydraulic dilator used in conjunction with FLIP technology and not requiring concomitant fluoroscopy 55 . The standard surgical alternative to pneumatic dilation is a LHM, in which the circular muscle fibres of the LES are surgically divided. Because of the propensity of this procedure to cause reflux, LHM is usually combined with a partial fundoplication. An extensive literature has compared LHM with pneumatic dilation 51 , culminating in a multi center European randomized controlled trial comparing the two for the treatment of achalasia, which concluded that both approaches were ~90% effective with no statistically significant difference in therapeutic success between them 56, 57 . However, that trial (and all preceding trials) did not consider achalasia subtypes in their design or in their assessment of treatment efficacy. Both the data in TABLE 3 and a subsequent reassessment of the European achalasia trial 23 suggest that achalasia subtypes are of great rele vance in terms of treatment effectiveness. Indeed, in the European achalasia trial, the efficacy of pneumatic dilation for treating type II achalasia was 100%, significantly better than LHM (93%, P = 0.03). By contrast, treatment success in type III achalasia was achieved in 40% and 86% of patients for pneumatic dilation and LHM respectively, although the difference between the two techniques was not statistically significant because of small patients numbers (n = 10 and n = 8 respectively, P = 0.12). Considering that the cost of pneumatic dilation is substantially less than LHM and that the risk of oesophageal perforation between techniques is comparable (about 1% when performed by gastroenterologists with extensive experi ence with the procedures) 58 , these findings argue for pneumatic dilation as the preferred initial treatment for type II achalasia.
POEM
Coincident with the assimilation of HRM and the CC, the widespread adoption of the POEM procedure was a major development in achalasia therapeutics. The POEM procedure involves making a mucosal incision in the mid-oesophagus and creating a submucosal tunnel to the gastric cardia using a standard endoscope and electrocautery 59 . A circular muscle myotomy is then performed from within the submucosal tunnel, beginning at the gastric cardia and progressing proximally across the LES. Therein lies an important advantage of POEM over LHM: the myotomy performed with POEM can be longer if desired, potentially involving the entire length of smooth muscle oesophagus, whereas LHM is limited to the length of oesophagus that can be safely accessed from below the diaphragm. This benefit is especially relevant in type III achalasia, in which therapy limited to the LES (pneumatic dilation) has worse outcomes ( 60 . Treatments effective for type III achalasia might also prove effective for other spastic disorders also character ized by obstructive physiology of the smooth muscle oesophagus: distal oesophageal spasm and jackhammer oesophagus. The meta-analysis by Khan et al. 60 also reported a weighted pooled response rate of 72% (95% CI 55-83%) in jackhammer oesophagus and a response rate in distal oesophageal spasm of 88% (95% CI 61-97%), only 4% less than in type III achalasia 60 . However, it must be emphasized that these data are from short-term uncontrolled studies, and the appropriate indications for POEM that balance the bene fits and risks of the procedure, and the optimal length of myotomy, have yet to be defined. Similarly, the degree to which reflux after POEM is a problem remains to be determined. A randomized controlled trial published in 2017 comparing POEM with pneumatic dilation found the POEM procedure to be more efficacious in terms of therapeutic success, but also more likely to result in post-procedure reflux oesophagitis 61 . The preceding discussion makes no mention of medical treatments for achalasia, specifically botulinum toxin [62] [63] [64] [65] , calcium-channel blockers 66 , nitrates 66 and phosphodiesterase type 5 inhibitors 67 primarily because, although these agents provide some symptomatic benefit, they are not durable therapies and they do not halt the disease progression toward oesophageal decompensation characterized by dilatation and food retention. For example, in the case of botulinum toxin injected into the LES, about two-thirds of patients with achalasia report an improvement in dysphagia, but most relapse within a year and repeat treatments have diminished effectiveness, making it a poor firstline therapy [62] [63] [64] [65] . Nonetheless, these treatments can be useful in patients who are not candidates for definitive therapy because of severe comorbidity. They can also be useful in situations in which one is uncertain whether or not a patient has achalasia, for example in some of the achalasia syndromes detailed in TABLE 2. Clearly, there are substantial limitations to current knowledge on the optimal treatment of oesophageal motility disorders as we have come to understand them with HRM
. Although the CC v3.0 has helped clarify several issues, especially the varied phenotypes of achalasia, it has also led to the realization that there are circumstances beyond type I, II, and III achalasia in which therapies once reserved for achalasia seem appropriate. In these domains, theories regarding the optimal treatment for each entity are many but evidence remains thin [68] [69] [70] . Nonetheless, one needs to act on the best evidence available. Conclusions HRM and analysis algorithms, summarized in the CC v3.0, have led to a major restructuring in the classification of oesophageal motility disorders. The cardinal feature of achalasia, impaired LES relaxation, is now recognized to occur in several disease phenotypes: without peristalsis, with premature (spastic) distal oesophageal contractions, with pan-oesophageal pressurization, or with peristalsis. An immediate effect of this advance has been increased detection of achalasia, challenging previous epidemiological estimates of the incidence and prevalence of this disorder. Furthermore, without a disease-specific biomarker, no manometric pattern is absolutely sensitive or specific for idiopathic achalasia caused by a myenteric plexopathy and physiological testing reveals a number of syndromes, not meeting CC criteria for achalasia, which also bene fit from therapies formerly reserved for achalasia. Complementary assessment with FLIP or provocative maneuvers during HRM can be useful in defining these syndromes. The utility of these additional clinical assessment techniques has become particularly relevant with the development of the POEM procedure, a minimally invasive technique for performing a cali brated myotomy of the oesophageal circular muscle. Hence, with HRM and the CC v3.0 we have come to conceptualize oesophageal motility disorders by speci fic aspects of physiological dysfunction, potentially involving the LES and/or obstructive physiology of the distal smooth muscle oesophagus. A major implication of this approach is a shift in management strategy towards rendering treatment in a phenotypespecific manner; for example, POEM calibrated to patient-specific physio logy as defined by HRM for the spastic disorders, and pneumatic dilation for the disorders limited to the LES.
